Literature DB >> 21435508

Diamond Blackfan anemia treatment: past, present, and future.

Anupama Narla1, Adrianna Vlachos, David G Nathan.   

Abstract

Despite significant improvements in our understanding of the pathophysiology of Diamond Blackfan anemia (DBA), there have been few advances in therapy. The cornerstones of treatment remain corticosteroids, chronic red blood cell transfusions, and hematopoietic stem cell transplantation, each of which is fraught with complications. In this article, we will review the history of therapies that have been offered to patients with DBA, summarize the current standard of care, including management of side effects, and discuss novel therapeutics that are being developed in the context of the research into the roles of ribosomal haplo-insufficiency and p53 activation in Diamond Blackfan anemia.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21435508      PMCID: PMC3073777          DOI: 10.1053/j.seminhematol.2011.01.004

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  56 in total

1.  Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6.

Authors:  S Volarevic; M J Stewart; B Ledermann; F Zilberman; L Terracciano; E Montini; M Grompe; S C Kozma; G Thomas
Journal:  Science       Date:  2000-06-16       Impact factor: 47.728

2.  Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients. DBA group of Société d'Hématologie et d'Immunologie Pédiatrique (SHIP), Gesellshaft für Pädiatrische Onkologie und Hämatologie (GPOH), and the European Society for Pediatric Hematology and Immunology (ESPHI).

Authors:  T N Willig; C M Niemeyer; T Leblanc; C Tiemann; A Robert; J Budde; A Lambiliotte; E Kohne; G Souillet; S Eber; J L Stephan; R Girot; P Bordigoni; G Cornu; S Blanche; J M Guillard; N Mohandas; G Tchernia
Journal:  Pediatr Res       Date:  1999-11       Impact factor: 3.756

Review 3.  Ribosomopathies: human disorders of ribosome dysfunction.

Authors:  Anupama Narla; Benjamin L Ebert
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

Review 4.  Diamond-blackfan anemia and cyclosporine therapy revisited.

Authors:  A J Alessandri; P C Rogers; L D Wadsworth; J H Davis
Journal:  J Pediatr Hematol Oncol       Date:  2000 Mar-Apr       Impact factor: 1.289

5.  Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.

Authors:  James E Bradner; Raymond Mak; Shyam K Tanguturi; Ralph Mazitschek; Stephen J Haggarty; Kenneth Ross; Cindy Y Chang; Jocelyn Bosco; Nathan West; Elizabeth Morse; Katherine Lin; John Paul Shen; Nicholas P Kwiatkowski; Nele Gheldof; Job Dekker; Daniel J DeAngelo; Steven A Carr; Stuart L Schreiber; Todd R Golub; Benjamin L Ebert
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

Review 6.  How I treat Diamond-Blackfan anemia.

Authors:  Adrianna Vlachos; Ellen Muir
Journal:  Blood       Date:  2010-07-22       Impact factor: 22.113

7.  Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.

Authors:  Shilpee Dutt; Anupama Narla; Katherine Lin; Ann Mullally; Nirmalee Abayasekara; Christine Megerdichian; Frederick H Wilson; Treeve Currie; Arati Khanna-Gupta; Nancy Berliner; Jeffery L Kutok; Benjamin L Ebert
Journal:  Blood       Date:  2010-11-10       Impact factor: 22.113

Review 8.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

Review 9.  Androgens and erythropoiesis: past and present.

Authors:  S Shahani; M Braga-Basaria; M Maggio; S Basaria
Journal:  J Endocrinol Invest       Date:  2009-04-07       Impact factor: 4.256

10.  A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.

Authors:  Jillian L Barlow; Lesley F Drynan; Duncan R Hewett; Luke R Holmes; Silvia Lorenzo-Abalde; Alison L Lane; Helen E Jolin; Richard Pannell; Angela J Middleton; See Heng Wong; Alan J Warren; James S Wainscoat; Jacqueline Boultwood; Andrew N J McKenzie
Journal:  Nat Med       Date:  2009-11-22       Impact factor: 53.440

View more
  23 in total

Review 1.  Molecular pathogenesis and clinical management of Fanconi anemia.

Authors:  Younghoon Kee; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

Review 2.  Characterization, regulation, and targeting of erythroid progenitors in normal and disordered human erythropoiesis.

Authors:  Brian M Dulmovits; Jimmy Hom; Anupama Narla; Narla Mohandas; Lionel Blanc
Journal:  Curr Opin Hematol       Date:  2017-05       Impact factor: 3.284

3.  Functional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation.

Authors:  Ah Ram Kim; Jacob C Ulirsch; Stephan Wilmes; Ekrem Unal; Ignacio Moraga; Musa Karakukcu; Daniel Yuan; Shideh Kazerounian; Nour J Abdulhay; David S King; Namrata Gupta; Stacey B Gabriel; Eric S Lander; Turkan Patiroglu; Alper Ozcan; Mehmet Akif Ozdemir; K Christopher Garcia; Jacob Piehler; Hanna T Gazda; Daryl E Klein; Vijay G Sankaran
Journal:  Cell       Date:  2017-03-09       Impact factor: 41.582

4.  The Stomatological Complications of Diamond-Blackfan Anemia: A Case Report.

Authors:  Rita Fabiane Teixeira Gomes; Maria Cristina Munerato
Journal:  Clin Med Res       Date:  2016-02-10

Review 5.  Pure red cell aplasia.

Authors:  Robert T Means
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

6.  Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia.

Authors:  Katelyn E Gagne; Roxanne Ghazvinian; Daniel Yuan; Rebecca L Zon; Kelsie Storm; Magdalena Mazur-Popinska; Laura Andolina; Halina Bubala; Sydonia Golebiowska; Meghan A Higman; Krzysztof Kalwak; Peter Kurre; Michal Matysiak; Edyta Niewiadomska; Salley Pels; Mary Jane Petruzzi; Aneta Pobudejska-Pieniazek; Tomasz Szczepanski; Mark D Fleming; Hanna T Gazda; Suneet Agarwal
Journal:  Blood       Date:  2014-04-15       Impact factor: 22.113

7.  How I manage acquired pure red cell aplasia in adults.

Authors:  Carmelo Gurnari; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2021-04-15       Impact factor: 22.113

8.  Measuring Organ-Specific Translation Elongation Rate in Mice.

Authors:  Maxim V Gerashchenko; Vadim N Gladyshev
Journal:  Methods Mol Biol       Date:  2021

9.  Metformin-induced suppression of Nemo-like kinase improves erythropoiesis in preclinical models of Diamond-Blackfan anemia through induction of miR-26a.

Authors:  Mark C Wilkes; Kavitha Siva; Gianluca Varetti; Jacqueline Mercado; Ethan P Wentworth; Cristina A Perez; Mallika Saxena; Sharon Kam; Simryn Kapur; Jun Chen; Anu Narla; Bert Glader; Shou Lin; Manuel Serrano; Johan Flygare; Kathleen M Sakamoto
Journal:  Exp Hematol       Date:  2020-09-12       Impact factor: 3.084

10.  Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro.

Authors:  H Moniz; M Gastou; T Leblanc; C Hurtaud; A Crétien; Y Lécluse; H Raslova; J Larghero; L Croisille; M Faubladier; O Bluteau; L Lordier; G Tchernia; W Vainchenker; N Mohandas; L Da Costa
Journal:  Cell Death Dis       Date:  2012-07-26       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.